Liquidia Corp
NASDAQ:LQDA
Gross Margin
Liquidia Corp
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Liquidia Corp
NASDAQ:LQDA
|
1.2B USD |
58%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
763B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
368.9B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
233.1B CHF |
73%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
176.2B GBP |
82%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
199.3B CHF |
75%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
220.6B USD |
81%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139B USD |
74%
|
Liquidia Corp
Glance View
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Liquidia Corp's most recent financial statements, the company has Gross Margin of 58%.
You don't have any saved screeners yet